Identification and validation of a glycosyltransferase gene signature as a novel prognostic model for lung adenocarcinoma

Keyphrases

• Lung Adenocarcinoma 100%
• Gene Signature 100%
• Prognostic Model 100%
• Glycosyltransferase Genes 100%
• Potential Therapeutics 42%
• Expression Level 28%
• High-risk Population 28%
• Low-risk Group 28%
• Therapeutic Target 14%
• Risk Score 14%
• Low Risk 14%
• High Risk 14%
• MRNA Level 14%
• Overall Survival 14%
• Quantitative PCR 14%
• Clinical Data 14%
• MEK Inhibitor (MEKi) 14%
• Tumor Immune Microenvironment 14%
• Cancer Genome Atlas 14%
• Tumor-infiltrating Immune Cells 14%
• Group-based 14%
• Prognostic Biomarker 14%
• Immunohistochemical Staining 14%
• Gene Set 14%
• Multivariate Cox Regression Analysis 14%
• Molecular Function 14%
• Least Absolute Shrinkage and Selection Operator (LASSO) 14%
• Differentially Expressed mRNAs (DEmRNAs) 14%
• Atlas Data 14%
• ST3GAL6 14%
• Prognostic Signature 14%
• Prognostic Genes 14%
• GALNT2 14%
• C1GALT1 14%
• PLOD2 14%
• FUT1 14%

Biochemistry, Genetics and Molecular Biology

• Gene Signature 100%
• Glycosyltransferase 100%
• Real-Time Polymerase Chain Reaction 28%
• High Risk Population 28%
• Low Risk Population 28%
• MEK Inhibitor 14%
• Overall Survival 14%
• mRNA Expression Level 14%
• GALNT2 14%
• FUT1 14%
• Tumor Immune Microenvironment 14%
• Immune Infiltration 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Adenocarcinoma 100%
• Glycosyltransferase 100%
• Neoplasm 28%
• Malignant Neoplasm 14%
• Biological Marker 14%
• Overall Survival 14%
• Mitogen Activated Protein Kinase Kinase Inhibitor 14%
• Messenger RNA 14%